BioCryst Pharmaceuticals, Inc.
BCRX
$8.80
$0.222.56%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -457.98M | 263.86M | -8.78M | -35.71M | -53.47M |
| Total Depreciation and Amortization | 4.22M | 3.49M | 3.43M | 3.05M | 3.04M |
| Total Amortization of Deferred Charges | 149.00K | 544.00K | 544.00K | 544.00K | 544.00K |
| Total Other Non-Cash Items | 832.88M | 136.37M | 127.46M | 129.16M | 124.93M |
| Change in Net Operating Assets | -66.17M | -56.90M | -72.46M | -80.22M | -100.89M |
| Cash from Operations | 313.10M | 347.37M | 50.20M | 16.82M | -25.85M |
| Capital Expenditure | -2.73M | -2.47M | -2.34M | -1.06M | -1.03M |
| Sale of Property, Plant, and Equipment | 550.00K | 550.00K | 550.00K | -- | -- |
| Cash Acquisitions | -489.48M | -- | -- | -- | -- |
| Divestitures | -6.18M | -6.18M | -- | -- | -- |
| Other Investing Activities | 188.40M | -5.59M | 89.38M | 83.56M | 51.96M |
| Cash from Investing | -309.44M | -13.69M | 87.59M | 82.51M | 50.93M |
| Total Debt Issued | 400.00M | -- | -- | -- | -- |
| Total Debt Repaid | -335.06M | -334.76M | -137.98M | -77.68M | -1.83M |
| Issuance of Common Stock | 26.29M | 9.17M | 8.49M | 7.92M | 4.76M |
| Repurchase of Common Stock | -8.68M | -8.85M | -6.51M | -6.14M | -7.12M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -20.45M | -15.50M | -- | -- | -- |
| Cash from Financing | 62.09M | -349.93M | -135.99M | -75.90M | -4.18M |
| Foreign Exchange rate Adjustments | 747.00K | 1.27M | 38.00K | 1.36M | -145.00K |
| Miscellaneous Cash Flow Adjustments | 0.00 | 0.00 | -14.84M | -15.06M | -- |
| Net Change in Cash | 66.50M | -14.99M | -13.01M | 9.72M | 20.75M |